Renal Cell Carcinoma | Topics

Lenvatinib in Combination with Pembrolizumab or Everolimus Shows Promise for Advanced RCC
November 10, 2020

The phase 3 KEYNOTE-581/CLEAR trial (Study 307) demonstrated that both combinations saw meaningful improvements in the study’s primary end point of progression-free survival for patients with advanced renal cell carcinoma.

Lower Starting Dose of Lenvatinib in RCC Does not Meet Non-Inferiority Threshold
November 09, 2020

The results of the phase 2 Study 218 indicated that the lower starting dose of 14 mg of lenvatinib (Lenvima) did not meet the threshold for non-inferiority compared to the FDA-approved starting dose of 18 mg.

Cabozantinib Appears to be More Effective for Treating Advanced RCC Compared with Sunitinib
November 01, 2020

First-line cabozantinib was found to provide longer quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST) in patients with advanced renal cell carcinoma when compared with sunitinib.